Dual detection of *Legionella pneumophila* and *Legionella* species by real-time PCR targeting the 23S-5S rRNA gene spacer region

G. Yang, R. Benson, T. Pelish, E. Brown, J. M. Winchell and B. Fields
Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA

Abstract

Although the majority of cases of Legionnaires’ disease (LD) are caused by *Legionella pneumophila*, an increasing number of other *Legionella* species have been reported to cause human disease. There are no clinical presentations unique to LD and hence accurate laboratory tests are required for early diagnosis. Therefore, we designed a real-time PCR assay that targets the 23S-5S rRNA intergenic spacer region (23S-5S PCR) and allows for detection of all *Legionella* species and discrimination of *L. pneumophila* from other *Legionella* species. In total, 271 isolates representing 50 *Legionella* species were tested and the assay was validated using 39 culture-positive and 110 culture-negative patient specimens collected between 1989 and 2006. PCR-positive results were obtained with all 39 culture-positive samples (100% sensitivity). Specimens that tested positive according to 23S-5S PCR, but were culture-negative, were further analysed by DNA sequencing of the amplicon or the macrophage infectivity potentiator (*mip*) gene. In addition to *L. pneumophila*, *Legionella longbeachae*, *Legionella cincinnatiensis* and *Legionella micdadei* were identified in the specimens. The assay showed a 7-log dynamic range displaying a sensitivity of 7.5 CFU/mL or three genome equivalents per reaction. Sixty-one specimens containing viruses or bacteria other than *Legionellae* were negative according to 23S-5S PCR, demonstrating its specificity. Use of this assay should contribute to the earlier detection of respiratory disease caused by *Legionella* species, as well as to increased rates of detection.

Keywords: 23S-5S, *Legionella pneumophila*, *Legionella* species, Legionnaires’ disease, real-time PCR

Original Submission: 19 August 2008; Revised Submission: 10 November 2008; Accepted: 21 November 2008
Editor: G. Greub
Article published online: 28 April 2009

Clin Microbiol Infect 2010; 16: 255–261

Introduction

*Legionellae* are ubiquitous in natural and man-made aqueous environments. To date, at least 52 *Legionella* spp. have been identified (http://www.bacterio.cict.fr/l/legionella.html). Twenty-three species have been found to be associated with human diseases [1,2]. Approximately 80–90% of reported cases of Legionnaires’ disease (LD) are attributed to *Legionella pneumophila*; however, all species may cause infection, especially in immunocompromised hosts [1,3,4].

Legionnaires’ disease has no unique clinical or radiographic features [5,6], which may lead to inappropriate therapy and a poor prognosis. Therefore, a validated and rapid diagnostic assay is of great importance. Current laboratory criteria for ensuring a confirmed diagnosis of LD involve isolating *Legionellae* by culture and detecting *L. pneumophila* serogroup 1 antigen in urine or seroconversion. Although these methodologies have good specificity, they primarily detect *L. pneumophila*. Non-*pneumophila* *Legionella* spp. may grow on buffered charcoal yeast extract (BCYE) media, but it usually takes approximately 1–2 weeks of incubation time for identification. Some strains, such as *Legionella*-like amoebal pathogens, are very fastidious and require amoebal co-culture [7], which is laborious and impractical for clinical diagnosis. Therefore, infections caused by non-*pneumophila* species may not be diagnosed.

To address these deficiencies, molecular assays that target the nucleic acid of *Legionellae* have been developed, but their applications in clinical diagnosis are still limited. For example, the proportion of cases diagnosed by PCR and other genotypic methods in Europe from 1995 to 2004 accounts for <2% of cases of LD (*n* = 27,244) [8]. Reluctance to use PCR assays for diagnosis is partially attributable to: (i) post-amplification procedures that are laborious, time-consuming
and prone to carry-over contamination and false positivity, and (ii) limited assay optimization and validation. Here, we present a real-time PCR assay that allows rapid detection and differentiation of L. pneumophila from 50 non-pneumophilic species without the need for post-PCR manipulation. The assay has been optimized to ensure sensitivity and specificity and validation has been carried out using culture isolates and clinical specimens. This assay should increase the rate of detection of infection caused by non-pneumophilic strains of Legionella and contribute to early diagnosis of LD.

Materials and Methods

Bacterial and viral strains

Viruses and bacteria other than Legionella were used to test the specificity of the real-time PCR, including Bordetella pertussis, Bordetella parapertussis, Bordetella holmesii, Bordetella bronchiiseptica, Corynebacterium diphtheriae, Candida albicans, Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Escherichia coli, Haemophilus influenzae, Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma genitalium, Ureaplasma urealyticum, Mycoplasma arginini, Mycoplasma buccale, Mycoplasma faucom, Mycoplasma fermentans, Mycoplasma hyorhinis, Mycoplasma lipophilum, Mycoplasma orale, Mycoplasma penetrans, Mycoplasma pircum, Mycoplasma salivarium, Moraxella catarrhalis, Mycobacterium tuberculosis, Neisseria meningitidis, Neisseria elongata, Pseudomonas aeruginosa, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus salivarius, Streptococcus sanguinis, Streptococcus salofermentans, Streptococcus sutoralis, Streptococcus vestibularis, Streptococcus sinesis, Streptococcus gordonii, Streptococcus agalactiae, Streptococcus peroris, Streptococcus sanguinis, Streptococcus parasanguis, Streptococcus infantis, Streptococcus mitis, Streptococcus cristatus, Streptococcus oralis, Klebsiella pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, influenza A (H1, H3, H5), influenza B, severe acute respiratory syndrome (SARS), respiratory syncytial virus (A, B), human parainfluenza viruses (1, 2, 3), human metapneumovirus, and adenovirus. Each was cultured using appropriate agar, cells and medium.

Legionella strains were grown on BCYE agar at 35 °C with 2.5% CO₂ for 48–72 h. The incubation period for the culture of human specimens was 7 days. The bacteria derived from a single colony were harvested in water and subjected to genomic DNA purification.

Primers and probe design, synthesis and optimization

Primers targeting the 23S-5S rRNA intergenic spacer region conserved for all Legionella species were designed. The sequences of forward and reverse primers were 5'-GTA CTA ATT GGC TGA TTG TCT TGA CC-3' and 5'-CCT GGC GAT GAC CTA CTT TCG-3', respectively. Two probes were designed within the amplicon region. One is specific for L. pneumophila (5'-FAM ATC TC-3' and 5'-CalOrg-ATC GTG TAA ACT CTA ACT GCT TAC CAA ACC TGT GG-3' BHQ); the other recognizes all known Legionella species (5'-FAM ATC TC-G-3' AA-C-3'G AA 'T'-3'G AAA C-3'BHQ) (** denotes lock nucleic acid) and is referred to as the genus-wide probe or Legionella spp. probe.

All PCR reactions were performed in triplicate using the AgPath-ID One-Step RT-PCR kit (AM1005; Applied Biosystems, Inc., Foster City, CA, USA) and the 7900HT real-time PCR system (Applied Biosystems, Inc.) unless otherwise indicated.

Standard curve analysis and sensitivity determination

Genomic DNA was purified from L. pneumophila serogroup 1 using the KingFisher ML instrument (Thermo Fisher Scientific, Inc., Waltham, MA, USA) and the InvitMag kit (B-Bridge International, Inc., Sunnyvale, CA, USA) following the manufacturers' instructions. Genome equivalent (gEq), or single copy of genome, was calculated using a genome size of 3,397 × 10⁶ bp (GenBank accession no. NC_002942). Ten-fold serial dilutions of the genomic DNA spanning seven orders of magnitude were amplified using optimized primers and probes.

To determine the lower limit of detection (LLOD) for live bacteria, ten-fold serial dilutions of L. pneumophila serogroup 1 were streaked on BCYE plates. Bacterial colonies were manually counted. Colony counts of > 120 or < 20 were excluded from analysis. The bacteria were suspended in water and diluted to c. 100 CFU/mL. Genomic DNA was extracted as above from 1.5 mL of bacterial suspension. Five per cent of the purified DNA samples (n = 30) corresponding to c. 7.5 CFU/mL were amplified using the 7900HT real-time PCR system.

Clinical specimens

In total, 149 clinical specimens from 67 patients with respiratory disease possibly caused by Legionella infection were tested. The specimens were collected over a 17-year period (Table I). Cultures were performed on BCYE or selective media upon receipt. Retrospective studies were carried out using the remaining specimens, which had been stored at −80 °C, to validate the 23S-5S PCR assay. Analysis of the mip sequence was performed on all culture-negative, but PCR-positive, samples unless otherwise indicated (Table I) using the 3130XL Sequencer and BigDye X Terminator reagent and purification kit (Applied Biosystems, Inc.). The sequences were aligned with those in the National Center for Biotechnology Information (NCBI) database or the
online *mip*-based *Legionella* identification tool (http://www.hpa-bioinfotools.org.uk/mip_ID.html). Real-time PCR for the human RNase P gene was carried out in parallel to monitor reaction inhibition and DNA integrity.

**Results**

**Detection of *Legionella* spp. in clinical specimens**

The 149 patient specimens corresponded to 11 sample types (Table 1). The assay allowed detection of *Legionella* spp. in all 39 culture-positive specimens. Moreover, *Legionellae* were identified in 27 of 110 culture-negative samples. Specimens that were 23S-5S PCR-positive but culture-negative were confirmed by sequencing the amplicon or by amplifying the *mip* gene, which was subsequently sequenced [9]. Among the 27 culture-negative samples, 15 were positive for *L. pneumophila*, two were positive for *Legionella longbeachae*, one was positive for *Legionella cincinnatiensis* and one was positive for *Legionella micdadei*. Amplicon sequence analysis of *mip* or 23S-5S did not reveal significant homology with any known *Legionella* spp. in seven samples, suggesting potentially novel *Legionella* spp. (R. M. Ratcliff, personal communication, 2008). One sample was depleted and no sequence analysis was performed.

**Assay design and optimization**

One set of primers and two probes were designed within the same region, resulting in a singleplex dual-colour real-time PCR (Fig. 1a). PCR reactions were performed using the primers at working concentrations of 25–200 nM at two-fold intervals. The sensitivity was three orders of magnitude lower if the primer concentration was < 100 nM. The lowest cycle threshold (Ct) occurred with forward/reverse primers at 100 nM and 200 nM, respectively. Increasing the concentration from 200 nM to 800 nM did not improve sensitivity as Ct values remained nearly unchanged (p < 0.05). The probes were titrated similarly from 50 nM to 600 nM. Use of the *Legionella* spp. probe performed better at 400 nM. Higher probe concentration resulted in decreased sensitivity (data not shown).

**Amplification efficiency, reproducibility and sensitivity**

Linear regression analysis of the standard curves showed excellent correlation between the Ct value and the log copy number of the *Legionella* genome ($R^2 = 0.997$) over seven orders of magnitude. The efficiency of amplification was 100.7% and 102.6% for *L. pneumophila* and the genus-wide *mip* probe, respectively (Fig. 1b). The primers target the specific sites, even in the presence of high concentrations of *Legionella* genomic DNA (Fig. 1c).

The analytical sensitivity was assessed by amplifying *L. pneumophila* serogroup I DNA at a concentration of 3 gEq per PCR reaction. All samples were positive using the *Legionella* spp. probe ($n = 20$; $Ct = 34.59 ± 0.76$, coefficient of variation (CV) 2.22%) and 95% of the samples were

**TABLE 1. Clinical specimens for validating 23S-5S assay**

| Sample type                      | Cultures positive (+), n | PCR positive (+), n | PCR negative (−), n | Cultures (−)/PCR (+), n | mip sequence analysis of PCR+ but culture− samples | Total |
|----------------------------------|--------------------------|---------------------|---------------------|--------------------------|----------------------------------------------------|-------|
| Sputum                           | 9                        | 18                  | 40                  | 9                        | $L. pneumophila$ ($n = 5$)                          | 58    |
| Lung tissue                      | 24                       | 31                  | 28                  | 7                        | $L. longbeachae$ ($n = 2$)                          | 59    |
| Bronchoalveolar lavage           | 2                        | 3                   | 4                   | 1                        | $L. micdadei$ ($n = 1$)                             | 7     |
| Bronchial swab                   | 2                        | 2                   | 0                   | 0                        | Not applicable                                     | 2     |
| Nasopharyngeal swab              | 2                        | 2                   | 0                   | 0                        | Not applicable                                     | 2     |
| Blood                            | 0                        | 8                   | 0                   | 8                        | $L. pneumophila$ ($n = 2$)                          | 8     |
| Liver                            | 0                        | 0                   | 1                   | 0                        | Not applicable                                     | 1     |
| Trans-tracheal aspirate          | 0                        | 0                   | 1                   | 0                        | Not applicable                                     | 1     |
| Spleen                           | 0                        | 0                   | 1                   | 0                        | Not applicable                                     | 1     |
| Pleural fluid                    | 0                        | 1                   | 1                   | 1                        | $L. pneumophila$ ($n = 1$)                          | 2     |
| Formalin-fixed and paraffin      | 0                        | 1                   | 7                   | 1                        | $L. pneumophila$ ($n = 1$)                          | 8     |
| embedded tissue (FFPE)           |                          |                     |                     |                          |                                                    |       |
| Total number of specimens        | 39$^a$                    | 66                  | 83                  | 27                       | $L. pneumophila$ ($n = 1$)                          | 149   |
| Percentage of specimens          | 26%                      | 44%                 | 56%                 | 18%                      | 18%                                                | 100.0%|

$^a$mip sequence analysis for all culture−/PCR+ samples unless otherwise indicated.

$^b$No sample left for sequencing.

$^c$Not applicable for sequence analysis.

$^d$Positive for *Legionella pneumophila*.

CMI, 16, 255–261

© 2009 The Authors

Journal Compilation © 2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 255–261
positive using the \textit{L. pneumophila} probe (\(n = 20\); \(C_t = 35.51 \pm 0.96\), \(CV = 2.69\%\)). By contrast, no signals were detected from no-template controls (NTCs) \((n > 100)\) after 40 cycles of amplification. Therefore, the LLOD of the assay was \(c. 3 \text{ gEq per PCR reaction}\). For live bacteria, the assay detected \textit{L. pneumophila} serogroup 1 at \(7.5 \text{ CFU/mL} \ (n = 30); \) for the \textit{Legionella} spp. probe: \(C_t = 33.83 \pm 0.52\), \(CV = 1.53\%\); for the \textit{L. pneumophila} probe: \(C_t = 37.05 \pm 0.92\), \(CV = 2.48\%\). No amplification was detected in the NTCs \((n = 10)\).

### Accuracy and specificity

Genomic DNA isolated from the 271 strains representing the 50 \textit{Legionella} spp. listed in Table 2 were amplified and detected using the \textit{Legionella} spp. probe and the \textit{L. pneumophila}-specific probe. The \textit{L. pneumophila} probe did not cross-react with any non-\textit{pneumophila} species and accurately detected \textit{L. pneumophila}, despite the presence of high concentrations of genomic DNA.

Total nucleic acid (TNA) was purified from 61 bacterial and viral strains (listed in Materials and methods). The TNA quality was demonstrated by corresponding PCR amplifications. Although the concentration of the templates was relatively high (5 ng, or \(c. 1 \times 10^7\) gEq for an organism with a genome size of \(3.0 \times 10^6\) bp (GenBank accession no. NC_002942), none of the strains reacted with the \textit{Legionella} probes, yielding an analytical specificity of 100%.

### Discussion

The urine antigen (UA) test is increasingly used by clinicians in the diagnosis of LD, but it is limited to the detection of \textit{L. pneumophila} serogroup 1 [10]. Extensive use of the UA test has resulted in a decrease in the use of other diagnostic methods, thus reducing the frequency of identification of species other than \textit{L. pneumophila} serogroup 1 [11]. For example, a recent study of population-based surveillance of severe pneumonia in Thailand found no cases of \textit{L. pneumophila} serogroup 1 infection using a UA test, but serological evidence suggested that approximately 5% of cases of pneumonia may be caused by \textit{L. longbeachae} \((n = 397)\) [12]. This underscores the need for diagnostic tests for all \textit{Legionella} spp. In this study, we developed and validated a 23S-SS dual-colour real-time PCR assay. The LLOD of the assay was 3 gEq/reaction for genomic DNA or 7.5 CFU/mL for the live \textit{Legionella} strain. It can distinguish \textit{L. pneumophila} from non-\textit{pneumophila} \textit{Legionella} spp. and can detect \textit{Legionella} spp. from all culture-positive clinical specimens within 3 h without requiring post-PCR processing steps. We assessed the specificity of the assay by analysing the DNA sequence of the amplicon or the \textit{mip} gene and by assessing the reactivity with the non-\textit{Legionella} bacteria and viruses.

\textit{Legionella} is not part of the human flora; thus, the presence or absence of \textit{Legionella} DNA in specimens could be
The absence of unique clinical features or radiographic patterns complicates the diagnosis of LD. Among the 149 Legionella species used for evaluating the 23S-5S assay

| Legionella spp. | Strains, n |
|-----------------|------------|
| L. pneumophila   | 66         |
| L. oseidaius     | 1          |
| L. anisa         | 18         |
| L. beltrandii     | 1          |
| L. birminghamensis | 5       |
| L. bozeanae      | 31         |
| L. brunnii       | 1          |
| L. busenensis    | 1          |
| L. chernii       | 3          |
| L. cincinnatensis| 3          |
| L. drazsakii     | 2          |
| L. dumoffii      | 7          |
| L. erythra       | 3          |
| L. farfieldensis | 1          |
| L. fallonii      | 2          |
| L. feleki        | 7          |
| L. greesiana     | 1          |
| L. genoa species | 1          |
| L. gormani       | 4          |
| L. grataiano     | 1          |
| L. greybras      | 1          |
| L. haedelae      | 4          |
| L. haeolens      | 1          |
| L. jamestowniensis| 2         |
| L. jordani       | 2          |
| L. lasangenuis   | 2          |
| L. longbeachae   | 7          |
| L. londinensis   | 2          |
| L. lytza         | 1          |
| L. maceachnii    | 1          |
| L. macleodii     | 6          |
| L. maracca       | 1          |
| L. nagasaki      | 2          |
| L. naatarum      | 3          |
| L. oakridgensis  | 3          |
| L. pansens      | 2          |
| L. quateremis    | 3          |
| L. quintanii     | 8          |
| L. rawbothami    | 2          |
| L. rubulescens   | 3          |
| L. saintheinian  | 6          |
| L. sanctucius    | 1          |
| L. shakespearei  | 3          |
| L. spiritensis   | 3          |
| L. steigerwaldi  | 1          |
| L. stennis      | 2          |
| L. tucsonensis   | 4          |
| L. wadsworthii   | 2          |
| L. walteri      | 1          |
| L. westeri      | 2          |
| Unidentified Legionella | 31       |
| Total           | 271        |

clinically significant. In recent years, molecular methods based on nucleic acid testing (NAT) have been extensively explored for diagnosis of LD. Overall NAT can be assigned to four types of assay: (i) PCR amplification of the whole genome followed by restriction enzymatic digestion and gel analysis [13, 14]; (ii) PCR amplification of specific regions of the genome followed by sequencing analysis [15, 16]; (iii) DNA hybridization or fluorescent in situ hybridization (FISH) [17–19], and (iv) real-time PCR assays targeting 16S rRNA, the mip gene or the 23S-5S intergenic region [20–23]. A high rate of recombination in the 16S rRNA gene results in multiple heterogeneous copies in the genome, which may lead to erroneous species identification [24, 25]. The Legionella mip gene is highly variable, which makes designing a consensus probe to recognize all Legionella spp. virtually impossible [9]. The relatively conserved 23S-5S region allows the selection of primers and probes to detect L. pneumophila and Legionella spp. in a singleplex format. Three singleplex real-time PCR assays for identifying and differentiating L. pneumophila from other Legionella spp. have been reported [20–22]. These tests either require sequencing or melting curve analysis to distinguish L. pneumophila from other species, or lack specificity or validation using clinical specimens [20–22].

The availability of suitable patient samples for Legionella nucleic acid detection is limited. Oral pharyngeal swabs or nasopharyngeal swabs that are routinely taken from patients with respiratory infections may be less than ideal for Legionella-specific PCR testing unless the burden of Legionellae is high [26]. Collection of serum or urine samples is simple to perform, but the reported sensitivity varies from 30% to 86% for urine samples [27–29] and is < 60% for serum samples from patients with proven LD [30]. It appears that Legionella DNA in serum only peaks in the acute stage of infection [30]. In this study, the sensitivity observed with the archived serum samples was < 30% (data not shown). Bronchoalveolar lavage fluid, bronchial aspirates, lung biopsies, post-mortem tissue specimens and sputum appear to be more suitable for culture and PCR, but most of these specimens are not readily obtainable and are not usually taken for diagnosis [6, 31]. Nevertheless, these clinical specimens are valuable for validation of this diagnostic assay. The level of the impurities, such as human genomic DNA, protein and carbohydrates, varies among different types of specimen, and pathogen concentration in a clinical sample is significantly lower than that in laboratory cultures.

Culture provides definitive diagnosis and remains a reference standard for Legionellae identification, but its use in the diagnosis of LD continues to decline. The clinical samples used in this study and in others [21–23] were positive only for L. pneumophila, suggesting that some non-pneumophila species were not detected by culture (L. cincinnatensis, L. longbeachae and L. macleodii). Serological testing is generally limited to epidemiological studies and is unsuitable for diagnosis of acute LD because seroconversion does not occur until 2 weeks after the onset of illness and may even be absent in some patients [32].

In addition, the serological heterogeneity of Legionella spp. and antibody cross-reactions can lead to false-negative or false-positive results [33]. The goal of this study was to develop a molecular assay as a supplemental tool for diagnosis of LD caused by Legionella spp.
lung specimens collected from patients with possible LD, Legionella spp. was detected in only 44% of cases. It is possible that the infection in these patients was caused by other pathogens. For example, we detected Pseudomonas aeruginosa, Sphingomonas spp. and Eubacterium spp. in some culture-negative samples using 16S rRNA PCR and sequencing analysis (data not shown).

In conclusion, we have established a sensitive and specific real-time PCR assay that allows the detection of L. pneumophila and its differentiation from non-pneumophila species. Use of this assay in conjunction with currently recommended diagnostic tests should lead to increased rates of detection of respiratory disease caused by Legionella species.

Acknowledgements

We thank C. Whitney for her critical comments on our manuscript, and S. Schwartz, K. Thurman, M. da Gloria Carvalho, D. Erdman, M. Tondella and K. Tatti for providing viruses, DNA/RNA or bacteria strains.

Transparency Declaration

The authors have no conflicts of interest with commercial entities or any other third parties.

References

1. Muder RR, Yu VL. Infection due to Legionella species other than L. pneumophila. Clin Infect Dis 2002; 35: 990–998.
2. Berger P, Papazian L, Drencourt M et al. Amoeba-associated microorganisms and diagnosis of nosocomial pneumonia. Emerg Infect Dis 2006; 12: 248–255.
3. McNally C, Hackman B, Fields BS et al. Potential importance of Legionella species as aetiology in community-acquired pneumonia (CAP). Diagn Microbiol Infect Dis 2003; 48: 79–82.
4. Roig J, Sabria M, Pedro-Botet Maria L. Legionella spp.: community-acquired and nosocomial infections.Curr Opin Infect Dis 2003; 16: 145–151.
5. Gupta SK, Imperiale TF, Sarosi GA. Evaluation of the Hospital Winthrop-University criteria to identify Legionella pneumophila. Chest 2001; 120: 1064–1071.
6. Fields BS, Benson RB, Richard EB. Legionella and Legionnaires’ disease: 25 years of investigation. Clin Microbiol Rev 2002: 15: 506–526.
7. Adeleke AA, Fields BS, Benson RF et al. Legionella drozanskii sp. nov., Legionella rawborthami sp. nov., Legionella falconii sp. nov.: three unusual new Legionella species. Int J Syst Evol Microbiol 2001; 51: 1151–1160.
8. Diederen BM. Legionella spp., Legionnaires’ disease. J Infect 2008; 56: 1–12.
9. Ratcliffe RM, Lanson JA, Manning PA et al. Sequence-based classification scheme for the genus Legionella targeting the mip gene. J Clin Microbiol 1999; 36: 1560–1567.
10. Dominguez JA, Grali N, Pedrosa P et al. Comparison of the Binax Legionella urinary antigen enzyme immunoassay (EIA) with the Biostest Legionella urine antigen EIA for detection of Legionella antigen in both concentrated, non-concentrated urine samples. J Clin Microbiol 1998; 36: 2718–2722.
11. Benin AL, Benson RF, Besser RE. Trends in Legionnaires’ disease, 1980–1998: declining mortality, new patterns of diagnosis. Clin Infect Dis 2002; 35: 1039–1046.
12. Phares CR, Wangroongsarb P, Chantra S et al. Epidemiology of severe pneumonia caused by Legionella longbeachae, Mycoplasma pneumoniae, Chlamydia pneumoniae: 1-year, population-based surveillance for severe pneumonia in Thailand. Clin Infect Dis 2007; 45: e147–e155.
13. van Belkum A, Struelens M, Quint W. Typing of Legionella pneumophila strains by reaction-mediated polymerase chain fingerprinting DNA. J Clin Microbiol 1993; 31: 2198–2200.
14. Salloum G, Meugnier H, Reyrolle M et al. Identification of Legionella species by ribotyping, other molecular methods. Res Microbiol 2002; 153: 679–686.
15. Grattard F, Gineura C, Riffard S et al. Analysis of the genetic diversity of Legionella by sequencing the 23S-5S ribosomal intergenic spacer region: from phylogeny to direct identification of isolates at the species level from clinical specimens. Microbes Infect 2006; 8: 73–83.
16. Fry NK, Warwick S, Founders N et al. Use of 16S ribosomal RNA analyses to investigate the phylogeny of the family Legionellaceae. J Gen Microbiol 1991; 137: 1215–1222.
17. Ezaki T, Hashimoto Y, Yemamoto H et al. Evaluation of the microplate hybridization method for rapid identification of Legionella species. Eur J Clin Microbiol Infect Dis, 1990; 9: 213–217.
18. Fain JS, Bryan RN, Cheng L et al. Rapid diagnosis of Legionella infection by a non-isotopic in situ hybridization method. Am J Clin Pathol 1991; 95: 719–724.
19. Buchbinder S, Leitritz L, Trebesius K et al. Mixed lung infection by Legionella pneumophila, Legionella gormanii detected by fluorescent in situ hybridization. Infection 2004; 32: 242–245.
20. Stolhaug A, Bergh K. Identification, differentiation of Legionella pneumophila. Legionella spp. with real-time PCR targeting the 16S rRNA gene, species identification by mip sequencing. Appl Environ Microbiol 2006; 72: 6394–6398.
21. Reischl U, Linde HJ, Lehn R et al. Direct detection, differentiation of Legionella spp., Legionella pneumophila in clinical specimens by dual-colour real-time PCR, melting curve analysis. J Clin Microbiol 2002; 40: 3814–3817.
22. Herpers B L, de Jongh BM, Van der Zwalum K et al. Rapid diagnosis of Legionella pneumophila, Legionella gormanii detected by fluorescent in situ hybridization. J Gen Microbiol 2003; 149: 4815–4816.
23. Templeton KE, Scfettina SA, Sillekers P et al. Development, clinical evaluation of an internally controlled, single-tube multiplex real-time PCR assay for detection of Legionella pneumophila, other Legionella species. J Clin Microbiol 2003; 41: 4016–4021.
24. Harth E, Romero J, Torres R et al. Intragenomic heterogeneity, intergenic recombination among Vibrio parahaemolyticus 16S rRNA genes. Microbiology 2007; 8: 2640–2647.
25. Teysier C, Marchandin H, Simeon De Buochbery M et al. Atypical 16S rRNA gene copies in Ochrobactrum intermedium strains reveal a large genomic rearrangement by recombination between rrn copies. Bacterial J 2003; 185: 2901–2909.
26. Diederen BM, Peeters MF. Are oropharyngeal swabs suitable as samples for Legionella-specific PCR testing? J Clin Microbiol 2007; 45: 3482–3483.
27. Murdoch DR, Walford EJ, Jenning LC et al. Use of the polymerase chain reaction to detect Legionella DNA in urine, serum samples from patients with pneumonia. Clin Infect Dis 1996; 23: 475–480.
28. Helbig JH, Engelstadtor T, Maiwald M et al. Diagnostic relevance of the detection of Legionella DNA in urine samples by the polymerase chain reaction. Eur J Clin Microbiol Infect Dis 1999; 18: 716–722.
29. Mattiota-Bernard P, Waser S, Vrioni G. Detection of Legionella pneumophila DNA in urine, serum samples from patients with pneumonia. Clin Microbiol Infect 2000; 6: 223–225.
30. Diederen BM, de Jong CM, Movmouk F et al. Evaluation of real-time PCR for the early detection of Legionella pneumophila DNA in serum samples. J Med Microbiol 2007; 1: 94–101.
31. Den Boer JW, Yzerman EPF. Diagnosis of Legionella infection in Legionnaires' disease. Eur J Clin Microbiol Infect Dis 2004; 23: 871–878.
32. Harrison TG, Taylor AG. Timing of seroconversion in Legionnaires’ disease. [Letter.] Lancet, 1988; 2: 795.
33. Helbig JH, Luck PC, Kunz B et al. Evaluation of the Legionella Duopath lateral flow assay for identification of Legionella pneumophila, Legionella species culture isolates. Appl Environ Microbiol 2006; 72: 4489–4491.